Influence of glucocorticosteroids on bone metabolism in children with inflammatory bowel disease

Influence of glucocorticosteroid (GCS) therapy on mineralization and bone metabolism in children with inflammatory bowel disease (IBD) was studied. 113 children (64 males and 49 females) with IBD were included in the study. Bone mineral density (BMD) of lumbar spine (DEXA) was assessed. Level of serum osteocalcin (OC), C-terminal telopeptides (CTT), parathyroid hormone (PTH), serum calcium, alkaline phosphatase and 25 (OH) vitamin D was measured to evaluate bone metabolism. Therapy in all patients was studied: type of the therapy, duration, dosage. In all patient who received GCS cumulative dose was calculated. 74,3% patients received GCS. Median cumulative dose of GCS was 48,8 mg/kg, majority of patients received just one course of GCS. We found negative correlation of BMD with cumulative dose of GCS (r= -0,24, p<0,05). It was shown in the study that main parameters in patients who received GCS in cumulative dose less than 100 mg/kg were no difference than parameters in patients who didn’t receive any steroids. Thus we suppose that this dose of GCS is relatively safe for bone metabolism and mineralization.

воспалительные заболевания кишечника (ВЗК), минеральная плотность костной ткани, болезнь Крона, язвенный колит, глюкокортикостероиды, inflammatory bowel disease, bone mineral density, Crohn disease, ulcerative colitis, glucocorticosteroids